Zhejiang Cheng Yi Pharmaceutical Co., Ltd.

Zhejiang Cheng Yi Pharmaceutical Co., Ltd. Is a private Joint-stock enterprise with strong background, specialized in manufacturing more than 100 types of products, including APIs, advanced pharmaceutical intermediates and medical formulations and so on. Now it has become one of the largest manufacturers in Ribose, Nucleic Acid and relative pharmaceutical intermediates in the world. Cheng Yi Pharma, was established in the middle 60' s of last century, while through 40 years innovation and growth, it has successfully ranked into a main manufacturer for the pharmaceutical products. Cheng Yi Pharmaceutical Co., Ltd. not only built a strict cGMP quality assurance system, thoroughly certificated GMP by SFDA, ISO9001 and ISO14001 certificated, as well compliance with pharmaceutical regulatory requirements in developed countries of European and American, but also respectively registered DMF for several products in 29 countries and areas including American FDA, European Union, Australia, Canada and so on. Cheng Yi Pharma passed GMP audit by Australia TGA and successfully received inspection by many worldwide well-known multinational pharmaceutical corporations. Cheng Yi Pharma, on vigorously developing, was also established an enterprise in Jiangsu province, named Jiangsu Cheng Yi Pharmaceutical Co.,Ltd. which mainly manufactures API and intermediates by fermentation process. Cheng Yi Pharma has ten GMP workshops and one pilot plant. It can not only scale manufactures pharmaceutical products and intermediates bulky in good quality, but also can supply from small samples with kilogram grade to small batch size with hundred kilograms according to customer's requirement for the new-drug research. Cheng Yi Pharma gained high reputation from customers inland and overseas with its abundant experience in research, mature and high-efficient manufacturing process, as well the integrated products series and the earnest sincere service from end to end. The products are exported to more than twenty countries and regions including America , Japan , South Africa and Europe , South-east Asian and so on. In September 2010, Cheng Yi Pharma successfully passed the first globle GMP joint audit for Ribavirin, Azathioprine and 6-Mercaptopurine APIs, which raised by Australia TGA, US FDA, EU EMEA and Singapore HSA on its main products, quality system and plant facilities. Cheng Yi Pharma looks forward to cooperating with you, and be “win-win” together with you.